You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 The background of the four patients with recurrent malignant glioma (RMG)

From: Boron neutron capture therapy with bevacizumab may prolong the survival of recurrent malignant glioma patients: four cases

Case No. Age Sex Hist. RPA class Irradiated dose (Gy-Eq) BV cycles PsPD or RN Survival (Months from BNCT)
      Brain (Max) Tumor (Max) Tumor (Mini) (Months from BNCT)   
1 43 M AA 3 11.4 118 36.1 3 (11 M) RN 23 M, alive
2 41 M GBM 4 12.1 88.5 36.6 4 (14 M) RN 26 M, alive
3 60 M AA 3 10.8 110 82.3 6 (4 M) PsPD 16.5 M
4 34 F AOA 3 11.5 71.6 30.1 6 (2 M) PsPD 14 M
  1. Hist, histology; RPA, recursive portioning analysis; BV, Bevacizumab; PsPD, pseudoprogression; RN, radiation necrosis; BNCT, boron neutron capture therapy.